Literature DB >> 25107893

Metastatic index of non-small-cell lung cancer and long-term survival.

Michael Poullis1, Michael Shackcloth2, Richard Page2, Julius Asanti-Siaw2, Steven Woolley2, Neeraj Mediratta2.   

Abstract

AIM: We aimed to determine whether metastatic index is a factor determining long-term survival in patients undergoing curative resection for non-small-cell lung cancer.
METHODS: There were 2695 consecutive pulmonary resections performed between October 2001 and September 2011 in our institution; 1795 were potentially curative resections for non-small-cell lung cancer with bronchial margin length data available. Benchmarking against the International Association for the Study of Lung Cancer data set was performed. Cox multivariate analysis was undertaken. Metastatic index was defined as N stage× bronchial resection margin length.
RESULTS: Benchmarking failed to reveal any significant differences between our data and the International Association for the Study of Lung Cancer data set. Univariate analysis identified metastatic index as a significant factor determining long-term survival (p = 0.04). Cox regression demonstrated that metastatic index (hazard ratio 1.29, p = 0.0002), age (hazard ratio 1.02, p < 0.0001), body mass index (hazard ratio 0.98, p = 0.006), female sex (hazard ratio 0.65, p < 0.0001), T1 stage (hazard ratio 0.67, p < 0.0001), T2 stage (hazard ratio 2.13, p < 0.0001), T3 stage (hazard ratio 1.59, p = 0.03), forced expiratory volume in 1 s (hazard ratio 0.70, p < 0.0001), pneumonectomy (hazard ratio 1.43, p = 0.001), histology subtype adenosquamous (hazard ratio 3.77, p = 0.01) and squamous (hazard ratio 0.83, p = 0.03) were all significant determinants of long-term survival.
CONCLUSION: Metastatic index is a significant factor determining long-term survival in patents with adenocarcinoma undergoing potentially curative surgery with a lobectomy.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Bronchi; carcinoma; lung neoplasms; neoplasm staging; non-small-cell lung; prognosis

Mesh:

Year:  2014        PMID: 25107893     DOI: 10.1177/0218492314545833

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  3 in total

1.  Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis.

Authors:  J Wang; H Xu; S Zhou; D Wang; L Zhu; J Hou; J Tang; J Zhao; S Zhong
Journal:  Eur J Clin Nutr       Date:  2017-05-17       Impact factor: 4.016

2.  A thioredoxin reductase 1 inhibitor pyrano [3,2-a] phenazine inhibits A549 cells proliferation and migration through the induction of reactive oxygen species production.

Authors:  Qifan Ding; Hengyu Wang; Ying Wang; Yuanyuan Lu
Journal:  Mol Biol Rep       Date:  2022-07-02       Impact factor: 2.742

3.  Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer.

Authors:  Ching-Feng Wu; Jui-Ying Fu; Chi-Ju Yeh; Yun-Hen Liu; Ming-Ju Hsieh; Yi-Cheng Wu; Ching-Yang Wu; Ying-Huang Tsai; Wen-Chi Chou
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.